Onconic Therapeutics
476060.KQFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
11
Cost of Revenue
0
Gross Profit
11
Gross Margin
100.0%
Operating Income
-4
Operating Margin
-32.3%
Net Income
-6
Net Margin
-54.5%
EPS (Basic)
$-1.00
EPS (Diluted)
$-1.00
EBITDA
-7
EBITDA Margin
-59.5%
2023
12/31/2023
Revenue
16
Cost of Revenue
0
Gross Profit
16
Gross Margin
100.0%
Operating Income
2
Operating Margin
10.6%
Net Income
1
Net Margin
8.0%
EPS (Basic)
$0.00
EPS (Diluted)
$0.00
EBITDA
2
EBITDA Margin
13.8%
2022
12/31/2022
Revenue
0
Cost of Revenue
0
Gross Profit
0
Gross Margin
100.0%
Operating Income
-11
Operating Margin
-15618.5%
Net Income
-11
Net Margin
-15191.5%
EPS (Basic)
$-19.00
EPS (Diluted)
$-19.00
EBITDA
-10
EBITDA Margin
-14028.1%
2021
12/31/2021
Revenue
0
Cost of Revenue
0
Gross Profit
0
Gross Margin
100.0%
Operating Income
-6
Operating Margin
-13903.2%
Net Income
-11
Net Margin
-25247.7%
EPS (Basic)
$-20.00
EPS (Diluted)
$-20.00
EBITDA
-11
EBITDA Margin
-23835.8%